<VariationArchive RecordType="classified" VariationID="981934" VariationName="NM_014712.3(SETD1A):c.1602_1603del (p.Gly535fs)" VariationType="Deletion" Accession="VCV000981934" Version="3" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-04-25" DateCreated="2021-09-24" MostRecentSubmission="2021-09-24">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="970041" VariationID="981934">
      <GeneList>
        <Gene Symbol="SETD1A" FullName="SET domain containing 1A, histone lysine methyltransferase" GeneID="9739" HGNC_ID="HGNC:29010" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p11.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="30957754" stop="30984664" display_start="30957754" display_stop="30984664" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="30968614" stop="30995980" display_start="30968614" display_stop="30995980" Strand="+" />
          </Location>
          <OMIM>611052</OMIM>
          <Haploinsufficiency last_evaluated="2018-02-28" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SETD1A">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2018-02-28" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SETD1A">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_014712.3(SETD1A):c.1602_1603del (p.Gly535fs)</Name>
      <CanonicalSPDI>NC_000016.10:30965343:AG:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p11.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="30965344" stop="30965345" display_start="30965344" display_stop="30965345" variantLength="2" positionVCF="30965343" referenceAlleleVCF="CAG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="30976665" stop="30976666" display_start="30976665" display_stop="30976666" variantLength="2" positionVCF="30976664" referenceAlleleVCF="CAG" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>G535fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.30965344_30965345del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.30965344_30965345del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.30976665_30976666del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.30976665_30976666del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_052948.1" sequenceAccession="NG_052948" sequenceVersion="1" change="g.13051_13052del">
            <Expression>NG_052948.1:g.13051_13052del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_014712.3" sequenceAccession="NM_014712" sequenceVersion="3" change="c.1602_1603del" MANESelect="true">
            <Expression>NM_014712.3:c.1602_1603del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_055527.1" sequenceAccession="NP_055527" sequenceVersion="1" change="p.Gly535fs">
            <Expression>NP_055527.1:p.Gly535fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="611052.0007" DB="OMIM" />
        <XRef Type="rs" ID="2056124989" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_014712.3(SETD1A):c.1602_1603del (p.Gly535fs) AND Neurodevelopmental disorder with speech impairment and dysmorphic facies" Accession="RCV001261423" Version="3">
        <ClassifiedConditionList TraitSetID="57037">
          <ClassifiedCondition DB="MedGen" ID="C5436699">Neurodevelopmental disorder with speech impairment and dysmorphic facies</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2021-09-21" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-09-21" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-09-24" MostRecentSubmission="2021-09-24">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">32346159</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="57037" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="54558" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Neurodevelopmental disorder with speech impairment and dysmorphic facies</ElementValue>
                <XRef ID="MONDO:0033630" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NEDSID</ElementValue>
                <XRef Type="MIM" ID="619056" DB="OMIM" />
              </Symbol>
              <XRef ID="C5436699" DB="MedGen" />
              <XRef ID="MONDO:0033630" DB="MONDO" />
              <XRef Type="MIM" ID="619056" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2841238" SubmissionDate="2021-09-21" DateLastUpdated="2021-09-24" DateCreated="2020-10-25">
        <ClinVarSubmissionID localKey="611052.0007_NEURODEVELOPMENTAL DISORDER WITH SPEECH IMPAIRMENT AND DYSMORPHIC FACIES" title="SETD1A, 2-BP DEL, NT1602_NEURODEVELOPMENTAL DISORDER WITH SPEECH IMPAIRMENT AND DYSMORPHIC FACIES" />
        <ClinVarAccession Accession="SCV001438713" DateUpdated="2021-09-24" DateCreated="2020-10-25" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-09-21">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a 10.4-year-old girl (patient 6) with neurodevelopmental disorder with speech impairment and dysmorphic facies (NEDSID; 619056), Kummeling et al. (2021) identified a de novo heterozygous 2-bp deletion (c.1602_1603del, NM_014712.2) in the SETD1A gene, resulting in a frameshift and premature termination (Gly535AlafsTer12) before the catalytic domain. The mutation was found by routine diagnostic testing. Immunoblot analysis of patient cells showed decreased levels of the SETD1A protein compared to controls. Under stress conditions, patient cell showed elevated activation of the DNA damage response and increased DNA degradation compared to controls. The findings were consistent with a loss-of-function effect and SETD1A haploinsufficiency.</Attribute>
              <Citation>
                <ID Source="PubMed">32346159</ID>
              </Citation>
              <XRef DB="OMIM" ID="619056" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SETD1A" />
          </GeneList>
          <Name>SETD1A, 2-BP DEL, NT1602</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">2-BP DEL, NT1602</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="611052.0007" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">NEURODEVELOPMENTAL DISORDER WITH SPEECH IMPAIRMENT AND DYSMORPHIC FACIES</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2841238" TraitType="Disease" MappingType="Name" MappingValue="NEURODEVELOPMENTAL DISORDER WITH SPEECH IMPAIRMENT AND DYSMORPHIC FACIES" MappingRef="Preferred">
        <MedGen CUI="C5436699" Name="Neurodevelopmental disorder with speech impairment and dysmorphic facies" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

